ETIB tests safety and effectiveness of Baricitinib for chronic GVHD

Generating new understanding of GVHD and developing new treatments

The Center for Cancer Research has launched a new clinical trial focused on improving the treatment of chronic graft-versus-host disease (cGVHD), a common adverse reaction that may develop after certain bone marrow transplants, such as a hematopoietic stem cell transplant using donor cells. cGVHD is usually treated with steroids, but only about half of patients respond to treatment. This clinical trial, led by physician-scientist Steven Pavletic of the Experimental Transplantation and Immunology Branch, will study a drug called baricitinib that inhibits proteins within the immune system that may play a role in cGVHD.
View more information on this trial.

Summary Posted: Thu, 09/01/2016